Stock Forecast

  genOway Société anonyme ( ALGEN.PA) Stock. Should you Buy or Sell?    $ 3.70

-0.13 (-3.50 %)



genOway Société anonyme Analysis

Updated on 10-09-2022
Symbol ALGEN.PA
Price $3.70
Beta 0.506
Volume Avg. $6 thousand
Market Cap $30.32 M
52 Week Range $2.64 - $4.865


genOway Société anonyme opened the day at $3.70 which is -3.50 % on yesterday's close. genOway Société anonyme has a 52 week high of $4.865 and 52 week low of $2.64, which is a difference of $2.225. We like to see positive, upward trending shares, preferably with momentum. Market capitalization is $30.32 M and total net profit is $14018969 which means the company is trading at 2.16 times profit to market capitalization. Theoretically, if you were to buy genOway Société anonyme for $30.32 M, it would take 15 years to get your money back. genOway Société anonyme are in the Biotechnology space which will have a sweet spot and industry standard for net profit multiples.



Price Chart


1 D | All


Financials




genOway Société anonyme Stock Forecast - Is genOway Société anonyme a Buy or Sell?


DCF ScoreStrong Buy
ROE ScoreSell
ROA ScoreNeutral
DE ScoreBuy
PE ScoreStrong Sell
PB ScoreStrong Buy
Overall RecommendationBuy

Growth and Value


PE Ratio -34.154
Dividend Yiel 0.000
Net Profit Margin -0.065


Valuing genOway Société anonyme


Price Book Value Ratio 1.472 Price To Book Ratio 1.472
Price To Sales Ratio 2.212 Price Earnings Ratio -34.154


How liquid is genOway Société anonyme


Current Ratio 2.335
Quick Ratio 0.677


Debt


Debt Ratio 0.549 Debt Equity Ratio 1.219
Long Term Debt To Capitalization 0.379 Total Debt To Capitalization 0.424



Latest news about genOway Société anonyme






About genOway Société anonyme


CEO : Dr. Alexandre Fraichard
Sector : Healthcare
Industry : Biotechnology

Website : https://www.genoway.com

Exchange : Paris

Description :

genOway Société anonyme, a biotechnology company, develops, manufactures, commercializes, and sells of custom genetically modified mouse, rat, and cell line models worldwide. It produces customized mouse models, such as knockout (KO) and knockin (KI) mouse models; customized rat models, including constitutive and conditional KO, point mutation KI, and quick KI rat models; and customized cell lines, such as constitutive KO, point mutation KI, reporter KI, quick KI, and KI cell lines. The company also offers humanized immune checkpoint mouse models; immunodeficient and reconstituted mouse and rat strains models; humanized immune target models; other mouse and rat catalog models; and immune checkpoint catalog cell lines. It serves pharmaceutical and life science companies, and academic institutes. The company was founded in 1999 and is headquartered in Lyon, France.


My Newsletter

Sign Up For Updates & Newsletters